Why Pittsburgh biotech company Carmell Therapeutics is going public

PITTSBURGH — Why is Carmell Therapeutics, poised to become the newest public company in the Pittsburgh region, taking that big step? CEO Randy Hubbell said it’s the right move for the Pittsburgh-based biotech company, which is a spinout of Carnegie Mellon University and is getting ready for the day when its first products will be commercialized.

Carmell, which began in 2008, fits in a space that isn’t easily categorized in the life sciences industry. It has developed plasma-based bioactive materials, which go into the body and safely deliver biologic medicine to either help bones or tissues heal quickly.

Read more from the Pittsburgh Business Times.